Market Research Logo

Neurological Disorder Diagnostics Market - Global Forecast to 2026

Neurological Disorder Diagnostics Market - Global Forecast to 2026

Neurological disorder diagnostic tools are those used in diagnosis of various neurological disorders. Neurological disorders can be diagnosed with the use of imaging and in vitro diagnostics techniques. Imaging techniques such as Computed Tomography (CT) and Magnetic Resonance Imaging (MRI) are used to create detailed images of organs, bones, soft tissue, blood vessels and different parts of body, while vitro diagnostic techniques consists of techniques such as biopsy, biomarker, blood test, urine test, and genetic testing.
Market Dynamics
Product launches and approvals of novel neurological diagnostic products is expected to be a major driver for growth of the global neurological disorder diagnostics. For instance, in 2016, Koninklijke Philips N.V. launched its latest Philips IQon Spectral CT in Canada. The latest Philips IQon Spectral CT is the world’s first and only spectral detector CT, designed specifically for spectral imaging. With a new dual-layer spectral detector, the IQon Spectral CT has added spectral resolution to conventional CT scanning. Increasing research and development activities for development of novel diagnosis techniques for neurological disorder is also expected to fuel the market growth. For instance, in 2017, researchers from Assistance Publique – Hôpitaux de Paris (AP-HP) in collaboration with ICM researchers (Inserm/CNRS/UPMC) and Metafora Biosystems, developed a diagnostic blood test for De Vivo disease, a rare neurological illness. Increasing prevalence of neurological disorders is also expected to increase demand for diagnostic devices in the near future. For instance, According to World Alzheimer Report 2016, around 47 million people are living with dementia worldwide, and this is expected to increase about three-fold to reach 131 million by 2050. Alzheimer is one of the leading causes of dementia and accounts for an estimated 60% to 80% of all of dementia cases, according to 2018 Alzheimer’s Facts and Figures published by Alzheimer’s Association.
Key features of the study:

  • This report provides in-depth analysis of neurological disorder diagnostics and provides market size (US$ Million) and Compound Annual Growth Rate (CAGR %) for the forecast period (2018 – 2026), considering 2017 as the base year
  • It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by leading players
  • It profiles leading players in the global neurological disorder diagnostics based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies, and future plans
  • Key companies covered as a part of this study include Siemens Healthineers, Koninklijke Philips N.V., General Electric Company, Esaote SpA, NeuroLogica Corporation, Masimo Corporation, York Instruments Ltd., Neusoft Medical Systems, and Canon Medical Systems Corporation.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launches, technology up-gradation, market expansion, and marketing tactics
  • The global neurological disorder diagnostics report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through the various strategy matrices used in analyzing the neurological disorder diagnostics
Detailed Segmentation:
  • Global Neurological disorder diagnostics, By Technology :
  • Imaging
  • Computed Tomography (CT)
  • Magnetic Resonance Imaging (MRI)
  • Nuclear Medicine Imaging
  • Positron Emission Tomography (PET)
  • Single-Photon Emission Computed Tomography (SPECT)
  • Near Infrared Spectroscopic Imaging (NIRS)
  • Electroencephalography (EEG)
  • Magnetoencephalography (MEG)
  • In Vitro Diagnostics
  • Biomarker
  • Biopsy
  • Others
  • Global Neurological disorder diagnostics, By Disease Indication:
  • Genetic Neurological Disorders
  • Alzheimer’s Disease (AD)
  • Parkinson’s Disease (PD)
  • Amyotrophic Lateral Sclerosis (ALS)
  • Huntington's Disease (HD)
  • Others
  • Immunological Neurological Disorders
  • Multiple Sclerosis
  • Others
  • Paraneoplastic Syndrome
  • Paraproteinemic neuropathies
  • Others
  • Global Neurological disorder diagnostics, By End User:
  • Hospitals & Clinics
  • Diagnostic Centers
  • Ambulatory Care Centers
  • Global Neurological disorder diagnostics, By Geography:
  • North America
  • Technology:
  • Imaging
  • Computed Tomography (CT)
  • Magnetic Resonance Imaging (MRI)
  • Nuclear Medicine Imaging
  • Positron Emission Tomography (PET)
  • Single-Photon Emission Computed Tomography (SPECT)
  • Near Infrared Spectroscopic Imaging (NIRS)
  • Electroencephalography (EEG)
  • Magnetoencephalography (MEG)
  • In Vitro Diagnostics
  • Biomarker
  • Biopsy
  • Others
  • By Disease Indication:
  • Genetic Neurological Disorders
  • Alzheimer’s Disease (AD)
  • Parkinson’s Disease (PD)
  • Amyotrophic Lateral Sclerosis (ALS)
  • Huntington's Disease (HD)
  • Others
  • Immunological Neurological Disorders
  • Multiple Sclerosis
  • Others
  • Paraneoplastic Syndrome
  • Paraproteinemic neuropathies
  • Others
  • By End User
  • Hospitals & Clinics
  • Diagnostic Centers
  • Ambulatory Care Centers
  • By Country:
  • U.S.
  • Canada
  • Europe
  • Technology:
  • Imaging
  • Computed Tomography (CT)
  • Magnetic Resonance Imaging (MRI)
  • Nuclear Medicine Imaging
  • Positron Emission Tomography (PET)
  • Single-Photon Emission Computed Tomography (SPECT)
  • Near Infrared Spectroscopic Imaging (NIRS)
  • Electroencephalography (EEG)
  • Magnetoencephalography (MEG)
  • In Vitro Diagnostics
  • Biomarker
  • Biopsy
  • Others
  • By Disease Indication:
  • Genetic Neurological Disorders
  • Alzheimer’s Disease (AD)
  • Parkinson’s Disease (PD)
  • Amyotrophic Lateral Sclerosis (ALS)
  • Huntington's Disease (HD)
  • Others
  • Immunological Neurological Disorders
  • Multiple Sclerosis
  • Others
  • Paraneoplastic Syndrome
  • Paraproteinemic neuropathies
  • Others
  • By End User
  • Hospitals & Clinics
  • Diagnostic Centers
  • Ambulatory Care Centers
  • By Country:
  • U.K.
  • Germany
  • Italy
  • France
  • Spain
  • Russia
  • Rest of Europe
  • Asia Pacific
  • Technology:
  • Imaging
  • Computed Tomography (CT)
  • Magnetic Resonance Imaging (MRI)
  • Nuclear Medicine Imaging
  • Positron Emission Tomography (PET)
  • Single-Photon Emission Computed Tomography (SPECT)
  • Near Infrared Spectroscopic Imaging (NIRS)
  • Electroencephalography (EEG)
  • Magnetoencephalography (MEG)
  • In Vitro Diagnostics
  • Biomarker
  • Biopsy
  • Others
  • By Disease Indication:
  • Genetic Neurological Disorders
  • Alzheimer’s Disease (AD)
  • Parkinson’s Disease (PD)
  • Amyotrophic Lateral Sclerosis (ALS)
  • Huntington's Disease (HD)
  • Others
  • Immunological Neurological Disorders
  • Multiple Sclerosis
  • Others
  • Paraneoplastic Syndrome
  • Paraproteinemic neuropathies
  • Others
  • By End User
  • Hospitals & Clinics
  • Diagnostic Centers
  • Ambulatory Care Centers
  • By Country:
  • China
  • India
  • Japan
  • ASEAN
  • Australia
  • South Korea
  • Rest of Asia Pacific
  • Latin America
  • Technology:
  • Imaging
  • Computed Tomography (CT)
  • Magnetic Resonance Imaging (MRI)
  • Nuclear Medicine Imaging
  • Positron Emission Tomography (PET)
  • Single-Photon Emission Computed Tomography (SPECT)
  • Near Infrared Spectroscopic Imaging (NIRS)
  • Electroencephalography (EEG)
  • Magnetoencephalography (MEG)
  • In Vitro Diagnostics
  • Biomarker
  • Biopsy
  • Others
  • By Disease Indication:
  • Genetic Neurological Disorders
  • Alzheimer’s Disease (AD)
  • Parkinson’s Disease (PD)
  • Amyotrophic Lateral Sclerosis (ALS)
  • Huntington's Disease (HD)
  • Others
  • Immunological Neurological Disorders
  • Multiple Sclerosis
  • Others
  • Paraneoplastic Syndrome
  • Paraproteinemic neuropathies
  • Others
  • By End User
  • Hospitals & Clinics
  • Diagnostic Centers
  • Ambulatory Care Centers
  • By Country:
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
  • Middle East
  • Technology:
  • Imaging
  • Computed Tomography (CT)
  • Magnetic Resonance Imaging (MRI)
  • Nuclear Medicine Imaging
  • Positron Emission Tomography (PET)
  • Single-Photon Emission Computed Tomography (SPECT)
  • Near Infrared Spectroscopic Imaging (NIRS)
  • Electroencephalography (EEG)
  • Magnetoencephalography (MEG)
  • In Vitro Diagnostics
  • Biomarker
  • Biopsy
  • Others
  • By Disease Indication:
  • Genetic Neurological Disorders
  • Alzheimer’s Disease (AD)
  • Parkinson’s Disease (PD)
  • Amyotrophic Lateral Sclerosis (ALS)
  • Huntington's Disease (HD)
  • Others
  • Immunological Neurological Disorders
  • Multiple Sclerosis
  • Others
  • Paraneoplastic Syndrome
  • Paraproteinemic neuropathies
  • Others
  • By End User
  • Hospitals & Clinics
  • Diagnostic Centers
  • Ambulatory Care Centers
  • By Country:
  • GCC
  • Israel
  • Rest of Middle East
  • Africa
  • Technology:
  • Imaging
  • Computed Tomography (CT)
  • Magnetic Resonance Imaging (MRI)
  • Nuclear Medicine Imaging
  • Positron Emission Tomography (PET)
  • Single-Photon Emission Computed Tomography (SPECT)
  • Near Infrared Spectroscopic Imaging (NIRS)
  • Electroencephalography (EEG)
  • Magnetoencephalography (MEG)
  • In Vitro Diagnostics
  • Biomarker
  • Biopsy
  • Others
  • By Disease Indication:
  • Genetic Neurological Disorders
  • Alzheimer’s Disease (AD)
  • Parkinson’s Disease (PD)
  • Amyotrophic Lateral Sclerosis (ALS)
  • Huntington's Disease (HD)
  • Others
  • Immunological Neurological Disorders
  • Multiple Sclerosis
  • Others
  • Paraneoplastic Syndrome
  • Paraproteinemic neuropathies
  • Others
  • By End User
  • Hospitals & Clinics
  • Diagnostic Centers
  • Ambulatory Care Centers
  • By Country:
  • Central Africa
  • South Africa
  • North Africa
  • Company Profiles
  • Siemens Healthineers*
  • Company Overview
  • Product Portfolio
  • Financial Performance
  • Key Strategies
  • Recent Developments
  • Koninklijke Philips N.V.
  • General Electric Company
  • Esaote SpA
  • NeuroLogica Corporation
  • Masimo Corporation
  • York Instruments Ltd.
  • Neusoft Medical Systems
  • Canon Medical Systems Corporation
“*” marked represents similar segmentation in other categories in the respective section.


1. Research Objective and Assumption
Research Objectives
Assumptions
Abbreviations
2. Market Purview
Report Description
Market Definition and Scope
Executive Summary
Market Snippet, By Technology
Market Snippet, By Disease Indication
Market Snippet, By End User
Market Snippet, By Region
Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
Market Dynamics
Drivers
Restraints
Market Opportunities
PEST Analysis
Porter’s Five Forces Analysis
4. Global Neurological Disorder Diagnostics Market, By Technology, 2016 – 2026 (US$ Mn)
Introduction
Market Share Analysis, 2018 and 2026 (%)
Y-o-Y Growth Analysis, 2017–2026
Segment Trends
Imaging
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Mn)
Segment Trends
Computed Tomography (CT)
Magnetic Resonance Imaging (MRI)
Nuclear Medicine Imaging
Positron Emission Tomography (PET)
Single-Photon Emission Computed Tomography (SPECT)
Near Infrared Spectroscopic Imaging (NIRS)
Electroencephalography (EEG)
Magnetoencephalography (MEG)
In Vitro Diagnostics
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Mn)
Biomarker
Biopsy
Others
5. Global Neurological Disorder Diagnostics Market, By Disease Indication, 2016 – 2026 (US$ Mn)
Introduction
Market Share Analysis, 2018 and 2026 (%)
Y-o-Y Growth Analysis, 2017–2026
Segment Trends
Genetic Neurological Disorders
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Mn)
Segment Trends
Alzheimer’s Disease (AD)
Parkinson’s Disease (PD)
Amyotrophic Lateral Sclerosis (ALS)
Huntington's Disease (HD)
Others
Immunological Neurological Disorders
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Mn)
Segment Trend
Multiple Sclerosis
Others
Paraneoplastic Syndrome
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Mn)
Paraproteinemic neuropathies
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Mn)
Segment Trend
Others
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Mn)
6. Global Neurological Disorder Diagnostics Market, By End User, 2016 – 2026 (US$ Mn)
Introduction
Market Share Analysis, 2018 and 2026 (%)
Y-o-Y Growth Analysis, 2017 – 2026
Segment Trends
Hospitals & Clinics
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Mn)
Diagnostic Centers
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Mn)
Ambulatory Care Centers
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Mn)
7. Global Neurological Disorder Diagnostics Market, By Region, 2016 – 2026 (US$ Mn)
Introduction
Market Share Analysis, By Region, 2018 and 2026 (%)
Y-o-Y Growth Analysis, For Regions, 2017–2026
North America
Market Size and Forecast, By Technology, 2016 – 2026 (US$ Mn)
Market Size and Forecast, By Disease Indication, 2016 – 2026 (US$ Mn)
Market Size and Forecast, By End User, 2016 – 2026 (US$ Mn)
Market Size and Forecast, By Country, 2016 – 2026 (US$ Mn)
U.S.
Canada
Europe
Market Size and Forecast, By Technology, 2016 – 2026 (US$ Mn)
Market Size and Forecast, By Disease Indication, 2016 – 2026 (US$ Mn)
Market Size and Forecast, By End User, 2016 – 2026 (US$ Mn)
Market Size and Forecast, By Country, 2016 – 2026 (US$ Mn)
U.K.
Germany
Italy
France
Spain
Russia
Rest of Europe
Asia Pacific
Market Size and Forecast, By Technology, 2016 – 2026 (US$ Mn)
Market Size and Forecast, By Disease Indication, 2016 – 2026 (US$ Mn)
Market Size and Forecast, By End User, 2016 – 2026 (US$ Mn)
Market Size and Forecast, By Country, 2016 – 2026 (US$ Mn)
China
India
Japan
ASEAN
Australia
South Korea
Rest of Asia Pacific
Latin America
Market Size and Forecast, By Technology, 2016 – 2026 (US$ Mn)
Market Size and Forecast, By Disease Indication, 2016 – 2026 (US$ Mn)
Market Size and Forecast, By End User, 2016 – 2026 (US$ Mn)
Market Size and Forecast, By Country, 2016 – 2026 (US$ Mn)
Brazil
Mexico
Argentina
Rest of Latin America
Africa
Market Size and Forecast, By Technology, 2016 – 2026 (US$ Mn)
Market Size and Forecast, By Disease Indication, 2016 – 2026 (US$ Mn)
Market Size and Forecast, By End User, 2016 – 2026 (US$ Mn)
Market Size and Forecast, By Country, 2016 – 2026 (US$ Mn)
Central Africa
South Africa
North Africa
Middle East
Market Size and Forecast, By Technology, 2016 – 2026 (US$ Mn)
Market Size and Forecast, By Disease Indication, 2016 – 2026 (US$ Mn)
Market Size and Forecast, By End User, 2016 – 2026 (US$ Mn)
Market Size and Forecast, By Country, 2016 – 2026 (US$ Mn)
GCC
Israel
Rest of Middle East
8. Competitive Landscape
Heat Map Analysis
Company Profiles
Siemens Healthineers
Company Overview
Product Portfolio
Key Developments
Financial Performance
Strategies
Koninklijke Philips N.V.
Company Overview
Product Portfolio
Key Developments
Financial Performance
Strategies
General Electric Company
Company Overview
Product Portfolio
Key Developments
Financial Performance
Strategies
Esaote SpA
Company Overview
Product Portfolio
Key Developments
Financial Performance
Strategies
NeuroLogica Corporation
Company Overview
Product Portfolio
Key Developments
Financial Performance
Strategies
Masimo Corporation
Company Overview
Product Portfolio
Key Developments
Financial Performance
Strategies
York Instruments Ltd.
Company Overview
Product Portfolio
Key Developments
Financial Performance
Strategies
Neusoft Medical Systems
Company Overview
Product Portfolio
Key Developments
Financial Performance
Strategies
Canon Medical Systems Corporation
Company Overview
Product Portfolio
Key Developments
Financial Performance
Strategies
9. Section
References
Research Methodology
About us and Sales Contact
*Browse 40 market data tables and 42 figures on “Neurological Disorder Diagnostics Market - Global forecast to 2026”.

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report